Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) insider Donald Bergstrom sold 10,269 shares of the company's stock in a transaction that occurred on Wednesday, November 18th. The shares were sold at an average price of $16.51, for a total value of $169,541.19. Following the completion of the transaction, the insider directly owned 386,609 shares of the company's stock, valued at approximately $6,382,914.59. This trade represents a 2.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Relay Therapeutics Stock Up 1.3%
Shares of RLAY stock traded up $0.20 during mid-day trading on Friday, reaching $16.11. The stock had a trading volume of 3,974,822 shares, compared to its average volume of 3,111,643. The firm has a market cap of $3.56 billion, a PE ratio of -10.67 and a beta of 1.74. Relay Therapeutics, Inc. has a one year low of $6.28 and a one year high of $21.27. The firm's 50 day simple moving average is $18.18 and its 200 day simple moving average is $15.66.
Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported ($0.37) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.03. Sell-side analysts forecast that Relay Therapeutics, Inc. will post -1.58 earnings per share for the current fiscal year.
Analyst Ratings Changes
RLAY has been the topic of several analyst reports. HC Wainwright boosted their price target on shares of Relay Therapeutics from $28.00 to $29.00 and gave the company a "buy" rating in a report on Thursday, August 20th. Zacks Research raised shares of Relay Therapeutics from a "strong sell" rating to a "hold" rating in a report on Thursday, August 20th. Citigroup reaffirmed a "market outperform" rating on shares of Relay Therapeutics in a report on Monday, August 10th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Relay Therapeutics in a research report on Friday, October 2nd. Finally, Citizens Jmp upped their target price on shares of Relay Therapeutics from $21.00 to $26.00 and gave the company a "market outperform" rating in a research note on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $27.00.
Read Our Latest Research Report on RLAY
Institutional Trading of Relay Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the business. Eurizon Capital SGR S.p.A. bought a new position in shares of Relay Therapeutics in the third quarter valued at about $33,000. Allworth Financial LP acquired a new position in Relay Therapeutics during the 2nd quarter worth about $34,000. GAMMA Investing LLC grew its holdings in Relay Therapeutics by 108.3% during the 3rd quarter. GAMMA Investing LLC now owns 2,850 shares of the company's stock worth $51,000 after acquiring an additional 1,482 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in Relay Therapeutics during the 2nd quarter worth about $62,000. Finally, KBC Group NV bought a new stake in Relay Therapeutics during the 1st quarter worth about $34,000. 96.98% of the stock is currently owned by institutional investors and hedge funds.
Relay Therapeutics Company Profile
(
Get Free Report)
Relay Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines for patients with serious diseases, with an emphasis on cancer. The company uses its computational drug discovery platform to study how proteins move and interact, aiming to identify drug targets and design therapies against them. Relay's research combines experimental biology, structural biology and computational methods. Its drug development programs have included candidates targeting cancer-related pathways, such as FGFR2 and PI3Kα.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Relay Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relay Therapeutics wasn't on the list.
While Relay Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.